Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
Arthritis Research & Therapy, 09/30/09
Schwartz N et al. – High uTWEAK levels are indicative of LN, as opposed to non-LN SLE and other healthy and disease control populations, and reflect renal disease activity in longitudinal followup. Thus, our study further supports a role for TWEAK in the pathogenesis of LN, and provides strong evidence for uTWEAK as a candidate clinical biomarker for LN.
Methods- Multicenter cohorts of SLE patients and controls
- Analysis of urinary TWEAK (uTWEAK) and/or serum TWEAK (sTWEAK) levels as potential biomarkers of LN
- Performance of TWEAK as a biomarker for nephritis compared to routinely used laboratory tests in lupus patients, including anti-double stranded DNA antibodies and levels of C3 and C4
- uTWEAK levels significantly higher in LN patients than in non-LN SLE patients and other disease control groups
- uTWEAK was better at distinguishing between LN and non-LN SLE patients than anti-DNA antibodies and complement levels
- High uTWEAK levels predicted LN in SLE patients with odds ratio of 7.36 (95% CI: 2.25 to 24.07)
- uTWEAK levels peaked during LN flares, and significantly higher during the flare than at 4 and 6 months prior or following the flare event
- A linear mixed-effects model showed significant association between uTWEAK levels in SLE patients and their disease activity over time
- sTWEAK levels not found to correlate with presence of LN or degree of nephritis activity
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/13/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Today in Systemic Lupus (SLE)...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus. A randomized controlled trial
Annals of Rheumatic Diseases, 11/10/09
Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study
Rheumatology, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


